[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Inna Chen, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,37,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100570921","observational-copenhagen-pancreatic-cancer-study-100570921",false,"NCT06713525","Observational Copenhagen Pancreatic Cancer Study","Copenhagen Pancreatic Cancer Study (COPAN)","COPAN","Inclusion Criteria:\n\nHistologically confirmed pancreatic cancer\n\nExclusion Criteria:\n\n* None","ALL",{"count":19,"type":20},8000,"ESTIMATED","OBSERVATIONAL","The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals diagnosed with PC and allows to investigate treatment outcomes and associated prognostic factors. Furthermore, the study aims to identify determinants of treatment management and treatment outcomes, including patient-reported outcomes.",[24],"Pancreatic Cancer","NOT_YET_RECRUITING","2024-11-27",{"date":28,"type":29},"2024-12-03","ACTUAL",{"date":31,"type":20},"2025-12",{"date":33,"type":20},"2036-12",{"name":35,"class":36},"Inna Chen, MD","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100409467","study-of-pro-in-patients-with-advanced-pancreatic-or-biliary-tract-cancer-bettereveryday-100409467","NCT04611867","Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)","Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or BiliaryTract Cancer (BetterEveryDay)","BetterEveryDay","Inclusion Criteria:\n\n* Adult (aged 18 and over)\n* Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer\n* Written informed consent before any study procedures\n* Planning to receive 1st line systemic anticancer therapy within ≤2 weeks\n* Performance status: ECOG 0-2\n* Access to the internet\n* Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member\n\nExclusion Criteria:\n\n* No mobile device\n* Exhibiting signs of overt psychopathology or cognitive dysfunction\n* Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments\n* Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.","18 Years",{"count":47,"type":20},274,"INTERVENTIONAL",[50],"NA","Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with pancreatic and lung cancer have highest rates of unplanned hospitalizations. Investigator initiated prospective \"Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)\" is to be initiated based on the great need for optimizing treatment care, reducing hospitalizations and improving outcomes.",[24,53],"Lung Cancer, Nonsmall Cell","RECRUITING","2024-09-30",{"date":57,"type":29},"2024-10-02",{"date":59,"type":29},"2021-08-17",{"date":61,"type":20},"2027-04-01",{"name":35,"class":36},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":63},"100309701","biomarkers-in-patients-with-pancreatic-cancer-biopac-100309701","NCT03311776","BIOmarkers in Patients With Pancreatic Cancer (\"BIOPAC\")","BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?","BIOPAC","Inclusion Criteria:\n\n* Age \\> 18 years\n* Histologically verified PC (ductal adenocarcinoma) or ampullary adenocarcinoma in a resected specimen; or histopathological confirmation of carcinoma in patients not undergoing surgery in the setting of clinical and radiological characteristics which, together with the pathology, are consistent with a diagnosis of PC independently of stage\n\nExclusion Criteria:\n\n• None","19 Years",{"count":74,"type":20},5000,"No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.",[24],[78,79,80,81,82,83],"Pancreatic cancer","Biomarkers","Biobank","Diagnostic biomarkers","Predictive biomarkers","Prognostic biomarkers","2023-02-28",{"date":86,"type":29},"2023-03-01",{"date":88,"type":29},"2008-07-03",{"date":90,"type":20},"2035-07-02",{"name":35,"class":36},""]